Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pergoveris start day 1 versus day 6 ovarian stimulation in women aged 36 to 40 undergoing ART
NL-OMON36626Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Aug 2011
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of luteinizing hormone, follitropin alfa in female infertility, sponsored by Merck & Co.. Started Aug 2011; status: active, not recruiting.
02
Drugs
luteinizing hormonefollitropin alfa
03
Conditions
female infertility
Beyond the preview
Go deeper on NL-OMON36626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36626.